David Rubinsztein FRS, FMedSci

David Rubinsztein is a Professor of Molecular Neurogenetics at the University of Cambridge where his laboratory investigates the relationship between autophagy and neurodegeneration. He completed medical training at the University of Cape Town and a doctoral degree in the Department of Medical Biochemistry at the University of Cape Town where he studied in the Unit for Cell Biology of Atherosclerosis.

Dr. Rubinsztein has made significant contributions to the fields of neurodegeneration and autophagy by demonstrating that autophagy regulates the clearance of aggregate-prone, intracytoplasmic proteins that cause neurodegenerative diseases, such as Alzheimer’s disease and Huntington’s disease. His laboratory is currently involved in the development of therapeutics to treat neurodegenerative disease by targeting autophagy, in addition to basic biology studies to better understand the mechanisms regulating autophagosome biogenesis. Dr. Rubinsztein is the Deputy Director of the Cambridge Institute for Medical Research (CIMR), a Wellcome Trust Principal Research Fellow, and the Academic Lead of the UK Alzheimer’s Research UK Cambridge Drug Discovery Institute.